Oruka Therapeutics (ORKA) Earnings Analysis

Oruka Therapeutics (ORKA) next reports earnings on 2026-08-10, consensus EPS -0.49 USD. Last quarter (2026-03-12) it beat with EPS -0.45 USD vs -0.61 USD est (+26.2%). It has beaten estimates in 4/4 recent quarters (100%). Trailing P/E -38.72.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does ORKA next report earnings?

Next earnings date2026-08-10
Consensus EPS estimate-0.49 USD
Revenue estimaten/a

ORKA earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-12-0.45 USD-0.61 USD+26.2%Beat
2025-11-12-0.55 USD-0.56 USD+1.8%Beat
2025-08-11-0.46 USD-0.48 USD+4.2%Beat
2025-03-06-0.49 USD-0.68 USD+27.9%Beat

Beat rate: 4/4 (100%) over reported quarters with consensus data.

ORKA valuation and analyst view

Trailing P/E-38.72
Trailing EPS-2.1071 USD
Price / book10.49
Dividend yield0.00%
Market cap3.49B
Analyst consensusBuy (9 buy / 0 hold / 0 sell)
Avg price target147.33 USD

Related research pages

Frequently asked questions

When is Oruka Therapeutics (ORKA)'s next earnings date?

Oruka Therapeutics is next scheduled to report on 2026-08-10, with a consensus EPS estimate of -0.49 USD.

Did ORKA beat earnings last quarter?

In its 2026-03-12 report, ORKA posted EPS of -0.45 USD versus a -0.61 USD estimate — a beat of 26.2%.

What is ORKA's earnings track record?

Over the last 4 reported quarters with consensus data, ORKA beat estimates 4 times (100%).

What is ORKA's current P/E ratio and EPS?

ORKA trades at a trailing P/E of -38.72 on trailing EPS of -2.1071038948633927 USD.

What do analysts rate ORKA?

Analyst consensus is "Buy" across 9 ratings (0 strong buy, 9 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 147.33 USD.